Salute e Benessere
Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Servier recently announced that Voranigo also won the Prix Galien USA Award in the Best Product for Orphan/Rare Diseases category, as well as the Prix Galien Poland Award.
The Prix Galien Award recognizes breakthrough products and outstanding research teams across the pharmaceutical, biotech, medtech, and digital health fields.
Voranigo has been granted marketing authorization for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and who are not in immediate need of radiotherapy or chemotherapy. in the
United States , Canada, Australia, Israel, the United Arab Emirates, Saudi Arabia, Switzerland,
Brazil , the United Kingdom, in
Japan and Europe (27 countries of the European Union as well as
Iceland , Liechtenstein and
Norway ).
presse@servier.com
Servier is an independent international pharmaceutical company. To find out more please visit the Group website: servier.com
Follow us on social media: LinkedIn, Facebook, X, Instagram
Logo: https://mma.prnewswire.com/media/2766991/5496713/Servier_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/serviers-voranigo-vorasidenib-receives-prix-galien-awards-across-multiple-regions-302635240.html